Otsuka Pharmaceutical, a pharmaceutical company, agreed to acquire Mindset Pharma, a drug discovery-based research and development company, C$80m. "Otsuka Pharmaceutical has designated psychiatry and neurology as one of its top priority therapeutic areas and has been developing antipsychotic agents with clinical significance on a global basis. With the addition of Mindset's novel compounds and synthesis processes, we expect this acquisition will further contribute to the treatment of patients suffering from psychiatric disorders," Makoto Inoue, Otsuka President and Representative Director.